Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: Results from a prospective, randomised, single-centre, pilot clinical trial

International Journal of Colorectal Disease

Volumn 27, Issue 12, 2012, Pages 1645-1650

  Zhang, R X ^a   Lu, Z H ^a   Wan, D S ^a   Wu, X J ^a   Ding, P R ^a   Kong, L H ^a   Pan, Z Z ^a   Chen, G ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Adverse event; Management; Neurotoxicity; Neurotropin; Oxaliplatin

Indexed keywords

CAPECITABINE; NEUROTROPIN; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHRONIC DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DYSESTHESIA; EXPLORATORY RESEARCH; FEMALE; HAND FOOT SYNDROME; HEPATOBILIARY DISEASE; HUMAN; HUMAN CELL; KIDNEY DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NEUTROPHIL COUNT; OPEN STUDY; PARESTHESIA; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFLEX DISORDER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84874413883     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1509-4     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA Cancer J Clin 58:71-96
2. Rixe O, Ortuzar W, Alvarez M et al (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52:1855-1865
3. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
4. De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
5. Schmoll H-J, Cartwright T, Tabernero J et al (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102-108
6. Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105
7. Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400
8. Wang W-S, Lin J-K et al (2007) Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 12:312-319
9. Extra JM, Marty M, Brienza S et al (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22
10. Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061
11. Lersch C, Schmelz R, Eckel F et al (2002) Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2:54-58
12. Penz M, Kornek GV, Raderer M (2001) Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 12:421-422
13. Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478-3483
14. Kawashiri T, Egashira N, Watanabe H, Ikegami Y, Hirakawa S, Mihara Y, Yano T, Ikesue H, Oishi R (2011) Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur J Pain 15(4):344-50
15. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21-33
16. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303
17. Torbersen T, Stalberg E, Brautaset NJ (1996) Generator sites for spontaneous activity in neuromyotonia. An EMG study. Electroencephalogr Clin Neurophysiol 101:69-98
18. Van Dijk JG, Lammers GJ, Wintzen AR, Molenaar PC (1996) Repetitive CMAPs: mechanisms of neural and synaptic genesis. Muscle Nerve 19:1127-1133
19. Vincent A, Beeson D, Lang B (2000) Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. Eur J Biochem 267:6717-6728
20. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na-channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25-32
21. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767-1774
22. Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4:889-901
23. Lahrmann H, Albrecht G, Drlicek M, Oberndorfer S, Urbanits S, Wanschitz J, Zifko UA, Grisold W (2001) Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle Nerve 24:834-838
24. Bai J, Nakamura H, Kwon YW et al (2003) Critical roles of thioredoxin in nerve growth factor-mediated signal transduction and neurite outgrowth in PC12 cells. J Neurosci 23:503-9
25. Price SA, Gardiner NJ, Duran-Jimenez B, Zeef LA, Obrosova IG, Tomlinson DR (2006) Thioredoxin interacting protein is increased in sensory neurons in experimental diabetes. Brain Res 1116:206-14
26. Kawashiri T, Egashira N, Itoh Y et al (2009) Neurotropin reverses paclitaxel-induced neuropathy without affecting anti-tumour efficacy. Eur J Cancer 45:154-163
27. Baek KK, Lee J, Park SH, Park JO et al (2010) Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 42(4):185-90
28. Kato K, Inaba Y, Tsuji Y et al (2011) A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. Jpn J Clin Oncol 41(1):63-8
29. Axel Grothey, Nikcevich DA (2011) Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer. NCCTG N04C7 29(4):421-427